Premature stroke and cardiovascular risk in primary Sjogren's syndrome

被引:12
|
作者
Zippel, Clara L. L. [1 ]
Beider, Sonja [1 ]
Kramer, Emelie [1 ]
Konen, Franz F. F. [2 ]
Seeliger, Tabea [2 ]
Skripuletz, Thomas [2 ]
Hirsch, Stefanie [1 ]
Jablonka, Alexandra [1 ]
Witte, Torsten [1 ]
Sonnenschein, Kristina [3 ]
Ernst, Diana [1 ]
机构
[1] Hannover Med Sch, Dept Rheumatol & Immunol, Hannover, Germany
[2] Hannover Med Sch, Dept Neurol, Hannover, Germany
[3] Hannover Med Sch, Dept Cardiol, Hannover, Germany
来源
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷
关键词
Sjogren syndrome; Raynaud disease; atherosclerosis; cardiovascular risk factors; cardiovasclar disease; vasculitis; EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI); stroke; SUBCLINICAL ATHEROSCLEROSIS; CLASSIFICATION CRITERIA; AMERICAN-COLLEGE; DATA-DRIVEN; PREVALENCE; CONSENSUS; MANIFESTATIONS;
D O I
10.3389/fcvm.2022.1048684
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionPrimary Sjogren's syndrome (pSS) is associated with an increased prevalence of traditional risk factors and cardiovascular diseases (CVDs). The study aimed to identify specific risk factors for CVD in pSS patients. MethodsPSS patients with and without CVD were compared. All patients fulfilled the EULAR/ACR classification criteria. Patients with CVD presented at least one of the following manifestations: myocardial infarction, transient ischemic attacks, ischemic or hemorrhagic stroke, peripheral artery disease, coronary artery disease, and carotid plaques. Data were collected by a standardized protocol and review of medical records. Results61/312 (19.6%) pSS patients presented with CVD. Traditional risk factors such as hypertension, hypercholesterinemia and diabetes (p < 0.05), pSS manifestations, in particular vasculitis (p = 0.033) and Raynaud's phenomenon (p = 0.018) were associated with CVD. Among patients with ischemic events (28/312, 9%), particularly cerebrovascular disease (n = 12/28, 42.9%), correlations with increased EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) (p = 0.039) and EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI) (p = 0.048) were observed. Age at first cerebrovascular event was 55.2 [48.9-69.6] years. Multivariate analysis confirmed hypertension [odds ratio (OR) 3.7, 95% confidence interval (CI) 1.87-7.18, p < 0.001], hypercholesterinemia (OR 3.1, 95% CI 1.63-5.72, p < 0.001), male gender (OR 0.4, 95% CI 0.17-0.78, p = 0.009), Raynaud's phenomenon (OR 2.5, 95% CI 1.28-4.82, p = 0.007), and CNS involvement (OR 2.7, 95% CI 1.00-7.15, p = 0.048) as independent CVD predictors. ConclusionRaynaud's phenomen as well as vasculitis and high ESSDAI have shown a significant association to CVD. PSS patients with cerebrovascular events were younger than expected. Knowledge about risk factors may help clinicians to identify pSS patients at risk for CVD. After diagnosis of pSS, patients should be screened for risk factors such as hypertension and receive appropriate therapy to prevent or at least reduce sequelae such as infarction. However, further investigations are necessary in order to achieve a reliable risk stratification for these patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Inflammation markers as risk factors for hypertension in primary Sjogren's syndrome
    Iatridi, Fotini
    Sgouropoulou, Vasiliki
    Pella, Eva
    Sarafidis, Pantelis
    Dimitroulas, Theodoros
    MODERN RHEUMATOLOGY, 2024, 34 (03) : 649 - 650
  • [42] Prognosis of Primary Sjogren's Syndrome with Special Regard to the Risk of Lymphoma
    Tomiak, C.
    AKTUELLE RHEUMATOLOGIE, 2008, 33 (06) : 325 - 336
  • [43] Clinical Course and Mortality Risk Factors in Primary Sjogren's Syndrome
    Horvath, F.
    Szanto, A.
    Papp, G.
    Zeher, M.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2015, 81 (05) : 366 - 366
  • [44] Primary Sjogren's syndrome as independent risk factor for subclinical atherosclerosis
    Novella-Navarro, Marta
    Luis Cabrera-Alarcon, Jose
    Luis Rosales-Alexander, Jose
    Juan Gonzalez-Martin, Jorge
    Carrion, Ofelia
    Garcia de la Pena, Paloma
    EUROPEAN JOURNAL OF RHEUMATOLOGY, 2022, 9 (01) : 20 - 25
  • [45] Subclinical Cardiovascular Involvement in Patients with Primary Sjogren Syndrome
    Batticciotto, Alberto
    Rigamonti, Federica
    Atzeni, Fabiola
    Antivalle, Marco
    Talotta, Rossella
    Boccassini, Laura
    Gianturco, Luigi
    Turiel, Maurizio
    Doria, Andrea
    Sarzi-Puttini, Piercarlo
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [46] Methotrexate in primary Sjogren's syndrome
    Skopouli, FN
    Jagiello, P
    Tsifetaki, N
    Moutsopoulos, HM
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1996, 14 (05) : 555 - 558
  • [47] Zidovudine in primary Sjogren's syndrome
    Steinfeld, SD
    Demols, P
    Van Vooren, JP
    Cogan, E
    Appelboom, T
    RHEUMATOLOGY, 1999, 38 (09) : 814 - 817
  • [48] Myocarditis and primary Sjogren's syndrome
    Levin, MD
    Zoet-Nugteren, SK
    Markusse, HM
    LANCET, 1999, 354 (9173): : 128 - 129
  • [49] Myocarditis and primary Sjogren's syndrome
    Yoshioka, K
    Tegoshi, H
    Yoshida, T
    Uoshima, N
    Kasamatsu, Y
    LANCET, 1999, 354 (9194): : 1996 - 1996
  • [50] Targeting primary Sjogren's syndrome
    Odani, Toshio
    Chiorini, John A.
    MODERN RHEUMATOLOGY, 2019, 29 (01) : 70 - 86